Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aytu BioPharma, Inc.
Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 26, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
July 20, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
AYTU
Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
June 29, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
June 13, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
May 16, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
April 25, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces Fast Track Designation Granted to AR101 for the Treatment of Vascular Ehlers-Danlos Syndrome
April 19, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Exposures
Product Safety
Tickers
AYTU
Aytu BioPharma Announces FDA Orange Book Listing of Newly Issued Patent for Cotempla XR-ODT(R)
March 23, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
AYTU
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 22, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma to Participate in the 34th Annual Roth Conference
March 08, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
March 07, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
March 02, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
March 02, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
February 14, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Completes $15 Million Debt Refinancing
January 31, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
January 04, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
January 03, 2022
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
December 13, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
AYTU
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
December 08, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
AYTU
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
November 23, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Tickers
AYTU
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
November 17, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
AYTU
Aytu BioPharma Reports First Quarter 2022 Financial Results
November 15, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Tickers
AYTU
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
November 08, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
September 30, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
September 27, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Tickers
AYTU
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
September 23, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces Formation of New Scientific Advisory Board to Support Development of AR101 for Vascular Ehlers-Danlos Syndrome
September 09, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Tickers
AYTU
Aytu BioPharma to Present at Upcoming September Investor Conferences
September 07, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Tickers
AYTU
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
July 27, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Tickers
AYTU
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
June 28, 2021
From
Aytu BioPharma, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
Tickers
AYTU
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.